Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector

Nanomedicine

Volumn 9, Issue 15, 2014, Pages 2291-2308

  Kesharwani, Prashant ^a   Tekade, Rakesh K ^b   Jain, Narendra K ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

cancer targeting; fourth generation PPI dendrimer; melphalan; pharmacodynamics; pharmacokinetics; stability; toxicity

Indexed keywords

AZETIDINE DERIVATIVE; DENDRIMER; DRUG CARRIER; FOLATE RECEPTOR; FOURTH GENERATION POLYPROPYLENEIMINE DENDRIMER; MELPHALAN; UNCLASSIFIED DRUG; POLY(PROPYLENEIMINE); POLYPROPYLENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLUORESCENCE ANALYSIS; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; RECEPTOR BINDING; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; NEOPLASMS;

ANIMALS; CELL LINE; DENDRIMERS; HUMANS; IN VITRO TECHNIQUES; MICE; MICE, INBRED BALB C; NEOPLASMS; POLYPROPYLENES;

EID: 84912123904     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.210     Document Type: Article

References (34)

1. Kesharwani P, Ghanghoria R, Jain NK. Carbon nanotube exploration in cancer cell lines. Drug Discov. Today 17, 1023-1030 (2012).
2. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 142, 557-567 (1993).
3. Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54, 675-693 (2002).
4. Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27, 4025-4033 (2006).
5. Yang T, Choi MK, Cui FD et al. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J. Control. Release 120, 169-177 (2007).
6. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J. Microencapsul. 26, 287-296 (2008).
7. Singh P, Gupta U, Asthana A, Jain NK. Folate and folate- PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug. Chem. 19, 2239-2252 (2008).
8. Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine 7, 295-304 (2011).
9. Tomalia DA, Baker H, Dewald JR et al. A new class of polymers: starburst dendritic molecules. Polym. J. 17, 117-132 (1985).
10. Kesharwani P, Gajbhiye V, Tekade RK, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. Curr. Drug Targets 12, 1478-1497 (2011).
11. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: let's meet the challenge. Int. J. Pharm. 394, 122-142 (2010).
12. Mishra V, Gupta U, Jain NK. Influence of different generations of poly(propylene imine) dendrimers on human erythrocytes. Pharmazie 65, 891-895 (2010).
13. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem. Rev. 109, 49-87 (2009).
14. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest. Radiol. 32, 748-754 (1997).
15. Patri AK, Kukowska-Latallo JF, Baker JR Jr. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Deliv. Rev. 57, 2203-2214 (2005).
16. Thakur S, Tekade RK, Kesharwani P, Jain NK. The effect of polyethylene glycol spacer chain length on the tumortargeting potential of folate-modified PPI dendrimers. J. Nanopart. Res. 15, 1625 (2013).
17. Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int. J. Pharm. 295, 221-233 (2005).
18. Brabander-van den Berg EMM, Meijer EW. Poly(propylene imine) dendrimers: large scale synthesis by heterogeneously catalyzed hydrogenation. Angew. Chem. Int. Ed. Engl. 32, 1308-1311 (1993).
19. Dutta T, Agashe, HB, Garg M, Balakrishnan P, Kabra M, Jain NK. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target. 15, 89-98 (2007).
20. Pinguet F, Joulia JM, Martel P, Grosse PY, Astre C, Bressolle F. High-performance liquid chromatographic assay for MPN in human plasma. Application to pharmacokinetic studies. J. Chromatogr. B Biomed. Appl. 686, 43-49 (1996).
21. Kumar PV, Asthana A, Dutta T, Jain NK. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J. Drug Target. 14, 546-556 (2006).
22. Singhai AK, Jain S, Jain NK. Evaluation of an aqueous injection of ketoprofen. Pharmazie 52, 149-151 (1997).
23. Agrawal P, Gupta U, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 28, 3349-3359 (2007).
24. Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK. Dendimer-mediated solubilization, formulation development and in vitro in vivo assessment of piroxicam. Mol. Pharm. 6, 940-950 (2009).
25. Casas A, Battah S, Di Venosa G et al. Sustained and efficient porphyrin generation in vivo using dendrimer conjugates of 5-ALA for photodynamic therapy. J. Control. Release 135, 136-143 (2009).
26. Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta 1770, 681-686 (2007).
27. Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nanoaggregates stabilized by doxorubicin-PEG-folate conjugate. J. Control. Release 100, 247-256 (2004).
28. Ying X, Wen H, Lu WL et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J. Control. Release 141, 183-192 (2010).
29. Kothari K, Bapat K, Korde A. Radiochemical and biological studies of 188Re labeled monoclonal antibody -CAMA3C8 specific for breast cancer. Ind. J. Nuc. Med. 19, 6-11 (2004).
30. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res. 5, 371-382 (1999).
31. VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh JE. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D 3 analog, EB1089. Endocrinology 139, 2102-2110 (1998).
32. Gajbhiye V, Jain NK. The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 32, 6213-6225 (2011).
33. Zhao XB, Lee RJ. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv. Drug Deliv. Rev. 56, 1193-1204 (2004).
34. Gupta U, Dwivedi SK, Bid HK, Konwar R, Jain NK. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int. J. Pharm. 393, 185-96 (2010).